SENEX BIOTECHNOLOGY, INC.

Address

715 Sumter Street
Columbia, SC, 29208-

Information

DUNS: 170943240
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Enhancing cytarabine efficacy in leukemia through CDK8/19 inhibition

    Amount: $299,891.00

    Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeuti ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. CDK8/19 inhibitor for the treatment of HER2+ breast cancer

    Amount: $299,993.00

    Approximately of breast cancers overexpress oncogenic tyrosine kinase receptor HER NEU Patients with metastatic HER cancer typically receive HER targeting monoclonal antibodies trastuzumab a ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  3. CDK8/19 inhibitors for therapy of advanced prostate cancer

    Amount: $240,750.00

    DESCRIPTION provided by applicant All existing forms of androgen deprivation therapy ADT the backbone of systemic prostate cancer PCa treatment involve inhibition of either ligand production ...

    SBIRPhase I2015Department of Health and Human Services
  4. CDK3-inhibiting anticancer agents

    Amount: $1,548,102.00

    DESCRIPTION (provided by applicant): This Phase II SBIR project is aimed at developing a novel type of drugs, termed SNX9-class compounds, with a unique combination of two anticancer activities. The f ...

    SBIRPhase II2011Department of Health and Human Services
  5. CDK3-inhibiting anticancer agents

    Amount: $107,000.00

    DESCRIPTION (provided by applicant): This Phase I SBIR project is aimed at developing a novel type of anticancer drugs, termed SNX9- class compounds. These compounds have a dual activity: (i) inhibiti ...

    SBIRPhase I2009Department of Health and Human Services
  6. Small Molecules Inducing BTG1 Transcription

    Amount: $107,001.00

    DESCRIPTION (provided by applicant): BTG1 is a transcription regulatory protein that interacts with different transcription factors and nuclear receptors. BTG1 acts as a tumor suppressor and as a medi ...

    SBIRPhase I2008Department of Health and Human Services
  7. Inhibitors of disease-promoting activities of senescence

    Amount: $802,501.00

    DESCRIPTION (provided by applicant): This project is aimed at developing a new class of drugs, which act by inhibiting pathogenic activities of senescent cells. Cell senescence occurring as a result o ...

    SBIRPhase II2008Department of Health and Human Services
  8. Inhibitors of disease-promoting activities of senescence

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The proposed project is aimed at developing a novel class of drugs against chronic diseases associated with old age. Such agents act by inhibiting a newly discover ...

    SBIRPhase I2006Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government